References
- Adcetris (brentuximab vedotin) [prescribing information]. Bothell, WA: Seattle Genetics; 2019.
- Gao S, Zhang M, Wu K, et al. Risk of adverse events in lymphoma patients treated with brentuximab vedotin: a systematic review and meta-analysis. Expert Opin Drug Saf. 2020;19(5):617–623.
- Gandhi MD, Evens AM, Fenske TS, et al. Pancreatitis in patients treated with brentuximab vedotin: a previously unrecognized serious adverse event. Blood. 2014;123(18):2895–2897.
- Urru SA, Mariotti E, Carta P, et al. Acute pancreatitis following brentuximab vedotin therapy for refractory Hodgkin lymphoma: a case report. Drugs R D. 2014;14(1):9–11.
- Maradana S, Akella P, Nalluru SS, et al. Hypertriglyceridemia induced pancreatitis due to brentuximab therapy: first case report. Cureus. 2019;11(7):e5138.
- Evens AM, Advani RH, Helenowski IB, et al. Multicenter phase II study of sequential brentuximab vedotin and doxorubicin, vinblastine, and dacarbazine chemotherapy in older patients with untreated classical Hodgkin lymphoma. J Clin Oncol. 2018;36(30):3015–3022.
- Maintenance and Support Services Organization [Homepage on the Internet]. Medical dictionary for regulatory activities. McLean (VA): MedDRA MSSO; 2013. [cited 2021 Dec 10]. Available from: http://www.meddra.org